Skip to content
DataLookout
Menu

NCT04711915

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 4 years later, enrollment reduced 67%.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 11 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment reduced: 30 → 10 participants Show 6 more changesShow less
    • Primary completion pushed from Jul 1, 2026 to Jul 1, 2030
    • Enrollment reopened
    • Eligibility criteria expanded, about 6 words
    • Study completion pushed from Dec 1, 2026 to Dec 1, 2030
    • Interventions: 0.1 mg/kg Dimethyltryptamine (DMT) (Drug), 0.3 mg/kg Dimethyltryptamine (DMT) (Drug) to 0.1 mg/kg Dimethyltryptamine (DMT) (Drug), 0.3 mg/kg Dimethyltryptamine (DMT) (Drug)
    • Site details revised
  2. Notable Primary completion date: Jul 1, 2025 to Jul 1, 2026
    • Study completion date: Dec 1, 2025 to Dec 1, 2026
    v11
  3. Notable Primary completion date: Dec 1, 2024 to Jul 1, 2025
    • Study completion date: Dec 1, 2024 to Dec 1, 2025
    v10
  4. Notable Primary and study completion dates pushed to Dec 1, 2024v9
  5. Notable Enrollment target: 6 to 30
    • Primary completion date: Dec 1, 2021 to Dec 1, 2023
    • Study completion date: Jun 1, 2022 to Jun 1, 2024
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v6
  2. Minor Start date changed from estimate of Mar 15, 2021 to Mar 17, 2021v5
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Mar 10, 2021 to Mar 15, 2021
    v4
  4. Minor Start date: Mar 1, 2021 to Mar 10, 2021v3
  5. Notable Eligibility criteria expanded, about 15 words
    • Primary endpoints revised (6)
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in Blood Pressure
Timeframe: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration
Change in Heart Rate
Timeframe: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration
Change in Psychedelic Effects
Timeframe: -60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration
Change in Anxiety
Timeframe: -60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration
Drug Reinforcing Effects
Timeframe: +120 minutes after DMT administration
Overall Tolerability assessed by the VAS
Timeframe: +120 minutes after DMT administration

Arms and interventions

0.1 mg/kg DMTActive comparator

0.1 mg/kg DMT administered intravenously

0.3 mg/kg DMTActive comparator

0.3 mg/kg DMT administered intravenously

Drugs: 0.1 mg/kg Dimethyltryptamine (DMT), 0.3 mg/kg Dimethyltryptamine (DMT)

Sites

1 site in 1 country

  • Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of MedicineWest Haven, Connecticut, United States